TWR Posted May 15, 2016 Share Posted May 15, 2016 OPDIVO Has a warning list as long as your leg and only costs $12500 a MONTH> For how much quality time??? Link to comment Share on other sites More sharing options...
Planteater Posted May 15, 2016 Share Posted May 15, 2016 Had a patient on it for trial last year- didn't tolerate it very well. Lots of increased weakness and SOB. Left the job before I found out if she actually developed pneumonitis or how long she survived. Link to comment Share on other sites More sharing options...
cbrsmurf Posted May 16, 2016 Share Posted May 16, 2016 Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer http://www.nejm.org/doi/full/10.1056/NEJMoa1504627 The median overall survival was 9.2 months (95% confidence interval [CI], 7.3 to 13.3) with nivolumab versus 6.0 months (95% CI, 5.1 to 7.3) with docetaxel. The risk of death was 41% lower with nivolumab than with docetaxel (hazard ratio, 0.59; 95% CI, 0.44 to 0.79; P<0.001). At 1 year, the overall survival rate was 42% (95% CI, 34 to 50) with nivolumab versus 24% (95% CI, 17 to 31) with docetaxel. The response rate was 20% with nivolumab versus 9% with docetaxel (P=0.008). The median progression-free survival was 3.5 months with nivolumab versus 2.8 months with docetaxel (hazard ratio for death or disease progression, 0.62; 95% CI, 0.47 to 0.81; P<0.001). The expression of the PD-1 ligand (PD-L1) was neither prognostic nor predictive of benefit. Treatment-related adverse events of grade 3 or 4 were reported in 7% of the patients in the nivolumab group as compared with 55% of those in the docetaxel group. There is real improvement in overall survival, but this is a last-ditch drug. Some pt's want to try everything, even to the end, and I think that's OK. Link to comment Share on other sites More sharing options...
TWR Posted May 17, 2016 Author Share Posted May 17, 2016 But at what dollar cost$$$$$$$$$$$$$$ Link to comment Share on other sites More sharing options...
Cideous Posted May 17, 2016 Share Posted May 17, 2016 3 months? That amount of money...for a few months? Mercy. Link to comment Share on other sites More sharing options...
cbrsmurf Posted May 19, 2016 Share Posted May 19, 2016 You can't always interpret a study in that fashion. You can have patients who lives are extended many months or years, while some may not gain any increased overall survival. Take a look at the study. At 2 year f/u, 25% on nivolumab are still alive while only 10% of patients on the control chemo are still alive. It's a lot of money, but we live in a capitalistic economy and healthcare is not excluded from that. Link to comment Share on other sites More sharing options...
tunafish Posted May 19, 2016 Share Posted May 19, 2016 3 months? That amount of money...for a few months? Mercy. Beats making F-35s in my book any day Link to comment Share on other sites More sharing options...
cbrsmurf Posted August 9, 2016 Share Posted August 9, 2016 Looks like Opdivo failed to extend life in the latest clinical trial. I believe the recommendation for advanced stage NSCLC treatment is being pulled. Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.